Highlight
This international cohort study investigates long-term outcomes in patients with platinum-sensitive recurrent ovarian cancer (PS-ROC) experiencing exceptional responses to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors maintained over 5 years. Key findings include remarkably high progression-free survival (PFS) rates at 7.5 and 10 years, evidence supporting potential treatment discontinuation without disease progression, low incidence of late-onset myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and genotype enrichment in the BRCA1 and BRCA2 functional domains among exceptional responders.